Steven Quay - Atossa Genetics Chairman of the Board and Presidentident, CEO
| ATOS Stock | USD 1.50 0.01 0.67% |
Chairman
Dr. Steven C. Quay, M.D., Ph.D. is Chairman of the Board, President, Chief Executive Officer of Atossa Genetics Inc., since April 2009. Prior to his work at the Company, Dr. Quay served as Chairman of the Board, President and Chief Executive Officer of MDRNA, Inc., a biotechnology company focused on the development and commercialization of RNAibased therapeutic products, from August 2000 to May 2008, and as its Chief Scientific Officer until November 30, 2008 . From December 2008 to April 2009, Dr. Quay was involved in acquiring the Companys assets and preparing the Companys business plan. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, is a former faculty member of the Department of Pathology, Stanford University School of Medicine, and is a named inventor on 14 U.S. and foreign patents covering the ForeCYTE Breast Aspirator. Including the patents for the ForeCYTE Breast Aspirator, Dr. Quay is a named inventor on 76 U.S. patents, 108 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the U.S. Food and Drug Administration
| Age | 63 |
| Professional Marks | Ph.D |
| Address | 107 Spring Street, Seattle, WA, United States, 98104 |
| Phone | 206 588 0256 |
| Web | https://atossatherapeutics.com |
Steven Quay Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steven Quay against Atossa Genetics stock is an integral part of due diligence when investing in Atossa Genetics. Steven Quay insider activity provides valuable insight into whether Atossa Genetics is net buyers or sellers over its current business cycle. Note, Atossa Genetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Atossa Genetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steven Quay over a year ago Acquisition by Steven Quay of 1873100 shares of Atossa Genetics subject to Rule 16b-3 | ||
Steven Quay over a year ago Acquisition by Steven Quay of 1873100 shares of Atossa Genetics subject to Rule 16b-3 | ||
Steven Quay over a year ago Acquisition by Steven Quay of 1873100 shares of Atossa Genetics subject to Rule 16b-3 | ||
Steven Quay over a year ago Acquisition by Steven Quay of 1873100 shares of Atossa Genetics subject to Rule 16b-3 |
Atossa Genetics Management Efficiency
The company has return on total asset (ROA) of (0.1784) % which means that it has lost $0.1784 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.288) %, meaning that it created substantial loss on money invested by shareholders. Atossa Genetics' management efficiency ratios could be used to measure how well Atossa Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.36 in 2024. At this time, Atossa Genetics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 4.2 M in 2024, whereas Return On Tangible Assets are likely to drop (0.33) in 2024.Similar Executives
| Found 11 records | CHAIRMAN Age | ||
| Avtar Dhillon | Inovio Pharmaceuticals | 56 | |
| James Bochnowski | Jaguar Animal Health | 74 | |
| Pankaj Mohan | Sonnet Biotherapeutics Holdings | 59 | |
| Robert Kay | Ibio Inc | 84 | |
| James Young | Novavax | 64 | |
| Jonathan MD | Ocean Biomedical | 55 | |
| Bruce Booth | AVROBIO | 42 | |
| David Dodd | GeoVax Labs | 74 | |
| Russell Plumb | Vaxart Inc | 56 | |
| Jack MD | Ocean Biomedical | 73 | |
| Seth Lederman | Tonix Pharmaceuticals Holding | 60 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.18 |
Atossa Genetics Leadership Team
Elected by the shareholders, the Atossa Genetics' board of directors comprises two types of representatives: Atossa Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atossa. The board's role is to monitor Atossa Genetics' management team and ensure that shareholders' interests are well served. Atossa Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atossa Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Heather CPA, Senior Officer | ||
| Lawrence Remmel, Independent Director | ||
| Kyle Guse, CFO, General Counsel, Secretary | ||
| Gerald PharmD, VP of Scientific Devel. and Medical Affairs | ||
| Janet Rea, Vice President - Regulatory Affairs and Quality | ||
| Gregory Weaver, Independent Director | ||
| Scott Youmans, COO | ||
| Steven Quay, Chairman of the Board and Presidentident, CEO | ||
| FCAP MD, CEO Chairman | ||
| Eric Zanten, Vice Relations | ||
| Stephen Galli, Independent Director | ||
| Richard MD, Interim Officer | ||
| Richard Steinhart, Director | ||
| ShuChih Chen, Director | ||
| Heather Rees, VP Accounting | ||
| Scott Gordon, IR Contact Officer | ||
| Pieter Poel, VP of European Commercial Operations | ||
| Cindy Atha, VP of Sales and Marketing | ||
| RAC MSPH, VP of Regulatory Affairs and Quality | ||
| Delly PHR, Vice Resources | ||
| CPA Esq, Gen CFO |
Atossa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atossa Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 89.47 M | ||||
| Shares Outstanding | 125.3 M | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 19.20 % | ||||
| Number Of Shares Shorted | 10.56 M | ||||
| Price To Earning | (0.62) X | ||||
| Price To Book | 2.30 X | ||||
| EBITDA | (31.35 M) |
Pair Trading with Atossa Genetics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atossa Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atossa Genetics will appreciate offsetting losses from the drop in the long position's value.Moving together with Atossa Stock
| 0.77 | NXL | Nexalin Technology | PairCorr |
Moving against Atossa Stock
| 0.8 | SINT | SINTX Technologies | PairCorr |
| 0.78 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
| 0.77 | HCAT | Health Catalyst Financial Report 14th of May 2024 | PairCorr |
| 0.7 | UNH | UnitedHealth Group Financial Report 12th of July 2024 | PairCorr |
| 0.68 | PRVA | Privia Health Group Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Atossa Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atossa Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atossa Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atossa Genetics to buy it.
The correlation of Atossa Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atossa Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atossa Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atossa Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atossa Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Atossa Stock please use our How to Invest in Atossa Genetics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Atossa Stock analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Atossa Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atossa Genetics. If investors know Atossa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atossa Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.24) | Return On Assets (0.18) | Return On Equity (0.29) |
The market value of Atossa Genetics is measured differently than its book value, which is the value of Atossa that is recorded on the company's balance sheet. Investors also form their own opinion of Atossa Genetics' value that differs from its market value or its book value, called intrinsic value, which is Atossa Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atossa Genetics' market value can be influenced by many factors that don't directly affect Atossa Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atossa Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atossa Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atossa Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.